Bristol Myers Squibb raises 2025 revenue and EPS guidance on Q3 earnings beat, driven by strong Eliquis and Opdivo sales.

The study tests two interventions: Elranatamab, a BCMA-CD3 bispecific antibody administered via injection, and Lenalidomide, an oral immunomodulatory drug. The goal is to determine which treatment ...

Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...

Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...

Sun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts ...

Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a study titled realMIND: A ...

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut ...

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. I could not think ...